Ferric pyrophosphate citrate
As of the edition of 20 October 2026, Ferric pyrophosphate citrate is a small molecule: marketed, first approved in 2015 (US); US protection ends in 2029.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2015
- Kind
- Small molecule
- Brand name
- Triferic
- First approved
- 23 January 2015 (US)
- Approvals on record
- 4 in 1 region
- Holder of the most recent approval
- Rockwell Medical
- Registered trials
- 17, 2 stopped early
- Disease areas
- Pregnancy and women's health; Urinary and reproductive; Blood and lymph; Nutrition and metabolism
US protection
US protection ends in 2029.
The last listed US drug-substance patent ends in 2029. The application that gives this date is held by Rockwell Medical.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 5 | 5 | 0 | 0 |
| Phase 2 | 8 | 6 | 0 | 1 |
| Phase 3 | 2 | 1 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 17 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Rockwell Medical | Originator and Lead sponsor of trials | 2007 to now |